- NorthX Biologics and Mendus are expanding their manufacturing collaboration to establish a platform for donor-derived memory natural killer (NK) cells using Mendus’ proprietary DCOne technology.
- Supported by funding awarded to Mendus by Vinnova, the initiative will focus on manufacturing memory NK cells from healthy donors for potential use in patients with acute myeloid leukemia (AML) following stem cell transplantation.
NorthX Biologics and Mendus are expanding their cell therapy manufacturing collaboration through a new initiative to establish a manufacturing platform for donor-derived memory natural killer (NK) cells. The platform will be based on Mendus’ proprietary DCOne technology and is supported by funding awarded to Mendus by Vinnova, Sweden’s innovation agency. The initiative adds to the companies’ ongoing collaboration on large-scale manufacturing of Mendus’ lead product candidate, vididencel.
Building on a partnership established in 2023, the new initiative will focus on manufacturing memory NK cells derived from healthy donors. The cells are being explored for potential therapeutic use in patients with acute myeloid leukemia (AML) following stem cell transplantation, where preventing disease relapse remains a clinical challenge.
The project was selected following an evaluation by an independent panel of external experts. Vinnova highlighted its potential to strengthen Sweden’s cell therapy manufacturing capacity and establish infrastructure of strategic importance for future commercialization.
“The funding would enable the company to advance its memory NK cell program, building on the existing collaboration with NorthX Biologics.”
Mendus CEO Erik Manting
“The initiative combines Mendus’ immunotherapy development expertise with NorthX Biologics’ cell therapy manufacturing capabilities and infrastructure.”
NorthX Biologics CEO Janet Hoogstraate
